JP2016507555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507555A5 JP2016507555A5 JP2015556930A JP2015556930A JP2016507555A5 JP 2016507555 A5 JP2016507555 A5 JP 2016507555A5 JP 2015556930 A JP2015556930 A JP 2015556930A JP 2015556930 A JP2015556930 A JP 2015556930A JP 2016507555 A5 JP2016507555 A5 JP 2016507555A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- immunologically active
- active fragment
- sequence defined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/761,087 | 2013-02-06 | ||
| USPCT/US2013/024995 | 2013-02-06 | ||
| PCT/US2013/024995 WO2013119714A1 (en) | 2012-02-06 | 2013-02-06 | Cd47 antibodies and methods of use thereof |
| US13/761,087 US9045541B2 (en) | 2012-02-06 | 2013-02-06 | CD47 antibodies and methods of use thereof |
| US201361815219P | 2013-04-23 | 2013-04-23 | |
| US61/815,219 | 2013-04-23 | ||
| PCT/US2013/053818 WO2014123580A1 (en) | 2013-02-06 | 2013-08-06 | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146460A Division JP6726238B2 (ja) | 2013-02-06 | 2018-08-03 | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507555A JP2016507555A (ja) | 2016-03-10 |
| JP2016507555A5 true JP2016507555A5 (enExample) | 2016-10-06 |
Family
ID=51300031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556930A Pending JP2016507555A (ja) | 2013-02-06 | 2013-08-06 | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
| JP2018146460A Active JP6726238B2 (ja) | 2013-02-06 | 2018-08-03 | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146460A Active JP6726238B2 (ja) | 2013-02-06 | 2018-08-03 | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP2953643B1 (enExample) |
| JP (2) | JP2016507555A (enExample) |
| KR (2) | KR102276974B1 (enExample) |
| CN (1) | CN105101997B (enExample) |
| AU (2) | AU2013377886B2 (enExample) |
| BR (1) | BR112015018851A2 (enExample) |
| CA (1) | CA2900468C (enExample) |
| CL (1) | CL2015002203A1 (enExample) |
| EA (1) | EA036963B1 (enExample) |
| ES (1) | ES2944477T3 (enExample) |
| IL (2) | IL240390B (enExample) |
| MX (2) | MX2015010115A (enExample) |
| NI (1) | NI201500103A (enExample) |
| NZ (1) | NZ710695A (enExample) |
| PE (1) | PE20151408A1 (enExample) |
| PH (1) | PH12015501729B1 (enExample) |
| SG (2) | SG10201706383XA (enExample) |
| WO (1) | WO2014123580A1 (enExample) |
| ZA (2) | ZA201505745B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| HK1216647A1 (zh) | 2012-12-12 | 2016-11-25 | Vasculox Inc. | 治疗性cd47抗体 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| US9969789B2 (en) | 2012-12-17 | 2018-05-15 | Trillium Therapeutics Inc. | Treatment of CD47+ disease cells with SIRP alpha-Fc fusions |
| JP6426693B2 (ja) | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CA2967379A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2016141328A2 (en) * | 2015-03-04 | 2016-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd47 |
| CN117964732A (zh) | 2015-08-07 | 2024-05-03 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
| EP3349787A4 (en) | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | THERAPEUTIC CD47 ANTIBODIES |
| AU2016326423A1 (en) | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| WO2017100462A2 (en) * | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| KR20220163516A (ko) * | 2016-01-11 | 2022-12-09 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
| SMT202400438T1 (it) | 2016-04-14 | 2024-11-15 | Ose Immunotherapeutics | Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche |
| KR20230035435A (ko) | 2016-04-15 | 2023-03-13 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 |
| WO2017184553A1 (en) * | 2016-04-18 | 2017-10-26 | Baylor College Of Medicine | Cancer gene therapy targeting cd47 |
| CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
| CA3029977A1 (en) | 2016-07-06 | 2018-01-11 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| US10277886B2 (en) | 2016-07-19 | 2019-04-30 | Gopro, Inc. | Mapping of spherical image data into rectangular faces for transport and decoding across networks |
| CN107955071B (zh) * | 2016-10-18 | 2021-03-26 | 上海赛远生物科技有限公司 | 人源抗人cd47抗体及其编码基因与应用 |
| CA2999058C (en) | 2016-10-20 | 2024-03-12 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| EP3538557A4 (en) * | 2016-11-08 | 2020-11-18 | Ablexis, LLC | ANTI-CD47 ANTIBODY |
| WO2018095428A1 (zh) * | 2016-11-28 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | Cd47抗体、其抗原结合片段及其医药用途 |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| WO2018137705A1 (en) * | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
| WO2018175790A1 (en) * | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| MX2019011624A (es) * | 2017-03-27 | 2019-12-05 | Celgene Corp | Metodos y composiciones para la reduccion de la inmunogenicidad. |
| EP4368206A3 (en) * | 2017-06-21 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Dosing parameters for cd47 targeting therapies to hematologic malignancies |
| JP7262440B2 (ja) * | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| CA3080640C (en) | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| CN110914304B (zh) * | 2017-11-10 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| JP7084045B2 (ja) * | 2017-11-10 | 2022-06-14 | アイ－マブ バイオファーマ ユーエス リミテッド | Ｃｄ４７抗体およびサイトカインを含む融合タンパク質 |
| SI3752190T1 (sl) | 2018-02-12 | 2022-11-30 | Forty Seven, Inc. | Shema zdravljenja proti raku z uporabo protiteles proti CD47 in proti CD20 |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| TW202448946A (zh) | 2018-05-25 | 2024-12-16 | 美商阿列克特有限責任公司 | 抗-sirpa 抗體及其使用方法 |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN110872350B (zh) * | 2018-08-31 | 2023-04-07 | 南京圣和药业股份有限公司 | 抗cd47抗体及其应用 |
| WO2020047651A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| BR112021008332A2 (pt) * | 2018-10-31 | 2021-08-03 | I-Mab Biopharma Us Limited | composição farmacêutica, proteína de fusão, anticorpo que se liga ao cd47 humano, e, métodos para tratar uma doença em um sujeito humano, para aumentar a seletividade de ligação de um anticorpo monoclonal ou biespecífico ao cd47 humano e para ligar um anticorpo cd47 ao cd47 humano |
| TW202045550A (zh) * | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
| MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN113461817B (zh) * | 2020-03-31 | 2025-04-18 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
| AR121805A1 (es) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | Anticuerpo anti-cd47 y usos del mismo |
| US20230159663A1 (en) * | 2020-04-24 | 2023-05-25 | Virtuoso Binco, Inc. | Bispecific antibodies for treating cd47-associated diseases |
| JP7789304B2 (ja) * | 2020-07-31 | 2025-12-22 | バイオ－テラ ソリュ－ションズ，エルティーディー． | Ｃｄ４７抗体及びその応用 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN114656566B (zh) * | 2020-12-23 | 2023-09-22 | 广东菲鹏制药股份有限公司 | 一种靶向cd47的抗体及其应用 |
| JP7699210B2 (ja) * | 2021-01-08 | 2025-06-26 | 北京韓美薬品有限公司 | Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント |
| CA3212398A1 (en) | 2021-03-17 | 2022-09-22 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2024515211A (ja) | 2021-04-27 | 2024-04-05 | ファイザー・インク | Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強 |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| US20250235504A1 (en) | 2021-10-29 | 2025-07-24 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| US20250367255A1 (en) | 2021-11-08 | 2025-12-04 | Pfizer Inc. | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents |
| CN118221812A (zh) * | 2022-12-14 | 2024-06-21 | 上海迈石生物技术有限公司 | 一种靶向cd47的单克隆抗体及其应用 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JPH10510700A (ja) | 1993-06-04 | 1998-10-20 | アメリカ合衆国 | アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法 |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
| US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| WO1999055369A1 (en) * | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| TWI241345B (en) * | 2000-03-10 | 2005-10-11 | Chugai Pharmaceutical Co Ltd | Apoptosis inducing polypeptide |
| AU2002315052A1 (en) * | 2001-05-15 | 2002-11-25 | Emory University | Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47 |
| ES2377720T3 (es) * | 2002-05-10 | 2012-03-30 | Purdue Research Foundation | Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. |
| US8101719B2 (en) * | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| JP2011524741A (ja) | 2008-05-27 | 2011-09-08 | 協和発酵キリン株式会社 | インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法 |
| AR073060A1 (es) * | 2008-08-14 | 2010-10-13 | Arana Therapeutic Ltd | Anticuerpos anti-il-12/il-23 |
| WO2011143624A2 (en) * | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| BR112013024574B1 (pt) * | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| KR102338833B1 (ko) * | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-08-06 WO PCT/US2013/053818 patent/WO2014123580A1/en not_active Ceased
- 2013-08-06 SG SG10201706383XA patent/SG10201706383XA/en unknown
- 2013-08-06 BR BR112015018851A patent/BR112015018851A2/pt not_active Application Discontinuation
- 2013-08-06 MX MX2015010115A patent/MX2015010115A/es unknown
- 2013-08-06 CA CA2900468A patent/CA2900468C/en active Active
- 2013-08-06 NZ NZ710695A patent/NZ710695A/en unknown
- 2013-08-06 EP EP13874383.6A patent/EP2953643B1/en active Active
- 2013-08-06 KR KR1020207030070A patent/KR102276974B1/ko active Active
- 2013-08-06 JP JP2015556930A patent/JP2016507555A/ja active Pending
- 2013-08-06 PE PE2015001628A patent/PE20151408A1/es active IP Right Grant
- 2013-08-06 SG SG11201506132PA patent/SG11201506132PA/en unknown
- 2013-08-06 KR KR1020157024103A patent/KR102170196B1/ko active Active
- 2013-08-06 AU AU2013377886A patent/AU2013377886B2/en active Active
- 2013-08-06 EA EA201500818A patent/EA036963B1/ru not_active IP Right Cessation
- 2013-08-06 CN CN201380075409.3A patent/CN105101997B/zh active Active
- 2013-08-06 ES ES13874383T patent/ES2944477T3/es active Active
- 2013-08-06 EP EP22185286.6A patent/EP4137518A1/en active Pending
-
2015
- 2015-08-04 MX MX2021008851A patent/MX2021008851A/es unknown
- 2015-08-06 NI NI201500103A patent/NI201500103A/es unknown
- 2015-08-06 CL CL2015002203A patent/CL2015002203A1/es unknown
- 2015-08-06 PH PH12015501729A patent/PH12015501729B1/en unknown
- 2015-08-06 IL IL240390A patent/IL240390B/en active IP Right Grant
- 2015-08-11 ZA ZA2015/05745A patent/ZA201505745B/en unknown
-
2018
- 2018-08-03 JP JP2018146460A patent/JP6726238B2/ja active Active
-
2019
- 2019-02-11 AU AU2019200942A patent/AU2019200942B2/en active Active
- 2019-08-12 ZA ZA2019/05292A patent/ZA201905292B/en unknown
-
2020
- 2020-05-10 IL IL274566A patent/IL274566B/en unknown